Nanosonics Limited · ASX:NAN
Nanosonics — H1 2014 Earnings Presentation
28 slides from Nanosonics's earnings presentation, Feb 24, 2014
Slide 1: Leader in Infection Control Solutions: 2014 Half Year Update
LEADER IN INFECTION CONTROL SOLUTIONS 2014 Half Year Update Michael Kavanagh, CEO and President 24 February 2013
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Company Overview
Company Overview 150% NAN ASX300 Healthcare All Ords 140% We aim to improve the safety of patients, clinics and their staff 130% 120% Proprietary automated system for low temperature, high level disinfection 110% ® First product, trophon EPR for 100% 1/7/13 29/7/13 26/8/13 23/9/13 21/10/13 18/
Slide 4: Fundamentals for the business continue to strengthen
Fundamentals for the business continue to strengthen Growing awareness of the Healthcare Acquired Infection risk associated with Imaging Regulation / Guidelines – Trends towards stricter controls (HLD) and Automation. Risk mitigation growing in importance under Accountable Healthcare models
Slide 5: Imaging procedure HAIs
Imaging procedure HAIs Imaging procedure HAIs – a critical subset of HAIs that are not often discussed. 0.9 - 9% of barrier sheaths and condoms leak.1, A meta-analysis has shown that 12.9% of transducers are contaminated with pathogenic bacteria following routine disinfection.2 HPV, a known
Slide 6: The case for automation
The case for automation The following national bodies recommend automated reprocessing over manual methods:1-3 Centers for Disease Control Robert Koch Institute Department of Health (USA).1 (Germany) .2 (UK) .3 Manual disinfection is known to lead to reduced protocol compliance.4 Any disinfectio
Slide 7: A new solution being embraced
A new solution being embraced…… The CEO of a group of radiology practices in Canada captures the issue perfectly: “Here we are, with a new $150K ultrasound machine and $15K probes to go with it that we’re cleaning with 1960s glutaraldehyde soaking technology.” Feisal Keshavjee, CEO, Radiology Consul
Slide 8: trophon EPR at the forefront of imaging related infection control
trophon® EPR at the forefront of imaging related infection control 8
Slide 9: 2014 H1 Financial Results
2014 H1 Financial Results nanosonics
Slide 10: Nanosonics: Financial Results 2014 H1
Nanosonics: Financial Results 2014 H1 H1 F14 H1 F13 % Change $million $million USA 7.994 3.034 163% Aus/NZ* 1.094 1.213 10% Europe +ROW .592 .173 242% Total Sales Revenue 9.68 4.42 119% Operating Expenses 10.3 9.4 10% Operating Loss 3.482 6.027 42% * Due to order timing Sales $'m H1 H2 7.2 10.5 Cash
Slide 11: Regional Update
Regional Update nanosonics
Slide 12: North America
North America Ron Bacskai President & CEO, Nanosonics Inc. Keith Koby John Corbett Vice President Sales Program Manager Lisa Davis Donna Fiorentino Business Development Northeast Regional Manager Sales Manager Kevin Markham Norm Rich Tom O’Neill Ray Beams Southeast Regional Western Regional North Ce
Slide 13: GE investment builds and gaining traction
GE investment builds and gaining traction ® Non-dilutive investment for trophon EPR sales and increased marketing activities continues ® GE funded dedicated trophon EPR sales team supporting the full North American ultrasound sales force in place Strategic Marketing investment continues 14
Slide 14: 38 of the top 50 Hospitals as of Jan 2014
38 of the top 50 Hospitals as of Jan 2014
Slide 15: 1286 USA locations as of Jan 2014
1286 USA locations as of Jan 2014 locations may have multiple units installed
Slide 16: United Kingdom
United Kingdom • Number of key hospitals adopting trophon EPR • Health Boards reviews nearing completion • Awareness activities progressing 17
Slide 17: Medicines & Healthcare products Regulatory Agency
Medicines & Healthcare products Regulatory Agency Government agency with responsibilities for standards of safety, quality & performance Medical Device Alert Ref: MDA/2012/037 Issued: 28 June 2012 Device Problem Action • Reusable transoesophageal, echocardiography, • The MHRA is aware of an incident
Slide 18: Health Boards review nearing completion
Health Boards review nearing completion News Ultrasound Probe Decontamination - National Full review of TV and TR reprocessing Survey Launched services in order to establish clear National Recommendations underway 4th October 2012 In August HFS launched a national survey of current decontamination p
Slide 19: Growing Market Awareness
nanoSonics LU’ Queen Elizabeth Hospital Birmingham NHS Foundation Trust PROBE DECONTAMINATION: A MULTIDISCIPLINARY aerish =
Slide 20: Whittington Hospital
Whittington Hospital In light of the serious cost pressures facing UK NHS Trust Hospitals there is a recognition of the potential issues which may result from inappropriate U/S probe care Trophon approved by Whittington Hospital
Slide 21: Germany
Germany • Clinical studies continue – nearing completion • Awareness strategies continue • Units in a number of key luminary sites 22
Slide 22: New Published evidence supporting trophon EPR
New Published evidence supporting trophon® EPR
Slide 23: trophon EPR a Finalist for M&K Award 2014
trophon® EPR a Finalist for M&K Award 2014 Management & Krankenhaus (M&K) • the leading newspaper for decisionmakers in German health care market • trophon® EPR a finalist in Hygine Sector
Slide 24: M&K Krankenhaus Award 2014
M&K Krankenhaus AWARD 2014 nanosonics
Slide 25: France – Awareness of risk continues to grow
France – Awareness of risk continues to grow Poor infection control practices in France may cause up to 30,000 people to develop an infection from intracavity ultrasound procedures. Of the four million yearly intracavity examinations the following 1 transmissions could occur: 63 HIV cases 1,624
Slide 26: Major share in Australian/NZ Market
Major share in Australian/NZ Market • Over 452 sites in Australia with trophon EPR • Australia’s largest medical imaging clinic network, I-MED, expanding adoption nationally • Adopted in 17 sites in NZ
Slide 27: Summary
Summary Fundamentals for the Business continue to strengthen Momentum continuing to build in North America Europe gaining traction First have revenue up 119% on PCP and net loss reduced by 42% Strong balance sheet with $21.65 million Accelerating sales growth expected 28
Slide 28: Slide 28